{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T20:05:47Z","timestamp":1786737947586,"version":"build-2736575974"},"reference-count":67,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:p>Hepatocellular carcinoma (HCC) is the third leading cause of cancer-related deaths worldwide, necessitating accurate and early diagnosis to guide therapy, along with assessment of treatment response. Response assessment criteria have evolved from traditional morphologic approaches, such as WHO criteria and Response Evaluation Criteria in Solid Tumors (RECIST), to more recent methods focused on evaluating viable tumor burden, including European Association for Study of Liver (EASL) criteria, modified RECIST (mRECIST) and Liver Imaging Reporting and Data System (\ufeffLI-RADS) Treatment Response (LI-TR) algorithm. This shift reflects the complex and evolving landscape of HCC treatment in the context of emerging systemic and locoregional therapies. Each of these criteria have\ufeff their \ufeffown nuanced strengths and limitations in capturing the detailed characteristics of HCC treatment and response assessment. The emergence of functional imaging techniques, including dual-energy CT, perfusion imaging, and rising use of radiomics, are enhancing the capabilities of response assessment. Growth in the realm of artificial intelligence and machine learning models provides an opportunity to refine the precision of response assessment by facilitating analysis of complex imaging data patterns. This review article provides a comprehensive overview of existing criteria, discusses functional and emerging imaging techniques, and outlines future directions for advancing HCC tumor response assessment.<\/jats:p>","DOI":"10.1097\/rct.0000000000001789","type":"journal-article","created":{"date-parts":[[2025,8,7]],"date-time":"2025-08-07T19:07:43Z","timestamp":1754593663000},"page":"167-179","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Response Assessment in Hepatocellular Carcinoma: A Primer for Radiologists"],"prefix":"10.1097","volume":"50","author":[{"given":"Nayla","family":"Mroueh","sequence":"first","affiliation":[{"name":"Department of Radiology, UPMC, Pittsburgh, PA Massachusetts General Hospital, Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinjin","family":"Cao","sequence":"additional","affiliation":[{"name":"Department of Radiology, UPMC, Pittsburgh, PA Massachusetts General Hospital, Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shravya","family":"Srinivas Rao","sequence":"additional","affiliation":[{"name":"Department of Radiology, UPMC, Pittsburgh, PA Massachusetts General Hospital, Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soumyadeep","family":"Ghosh","sequence":"additional","affiliation":[{"name":"Department of Radiology, UPMC, Pittsburgh, PA Massachusetts General Hospital, Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3914-9203","authenticated-orcid":false,"given":"Ok Kyu","family":"Song","sequence":"additional","affiliation":[{"name":"Department of Radiology, UPMC, Pittsburgh, PA Massachusetts General Hospital, Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sasiprang","family":"Kongboonvijit","sequence":"additional","affiliation":[{"name":"Department of Radiology, UPMC, Pittsburgh, PA Massachusetts General Hospital, Harvard Medical School, Boston, MA"},{"name":"Department of Radiology, Faculty of Medicine, King Chulalongkorn Memorial Hospital, Thai Red Cross Society, Chulalongkorn University, Bangkok, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anuradha","family":"Shenoy-Bhangle","sequence":"additional","affiliation":[{"name":"Department of Radiology, UPMC, Pittsburgh, PA Massachusetts General Hospital, Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Avinash","family":"Kambadakone","sequence":"additional","affiliation":[{"name":"Department of Radiology, UPMC, Pittsburgh, PA Massachusetts General Hospital, Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,3]]},"reference":[{"key":"R1-20260814","doi-asserted-by":"crossref","first-page":"S228","DOI":"10.3350\/cmh.2024.0824","article-title":"Hepatocellular carcinoma: updates on epidemiology, surveillance, diagnosis and treatment","volume":"31","author":"Hwang","year":"2025","journal-title":"Clin Mol Hepatol"},{"issue":"suppl 1","key":"R3-20260814","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1002\/hep.31288","article-title":"Epidemiology of hepatocellular carcinoma","volume":"73","author":"McGlynn","year":"2021","journal-title":"Hepatol Baltim Md"},{"key":"R4-20260814","doi-asserted-by":"crossref","first-page":"e14070","DOI":"10.1097\/MD.0000000000014070","article-title":"Clinical characteristics and prognosis of 2887 patients with hepatocellular carcinoma: a single center 14 years experience from China","volume":"98","author":"Wang","year":"2019","journal-title":"Medicine"},{"key":"R5-20260814","first-page":"228","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer Oxf Engl 1990"},{"key":"R6-20260814","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1148\/radiol.2018181494","article-title":"Liver Imaging Reporting and Data System (LI-RADS) version 2018: imaging of hepatocellular carcinoma in at-risk patients","volume":"289","author":"Chernyak","year":"2018","journal-title":"Radiology"},{"key":"R7-20260814","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1055\/s-0030-1247132","article-title":"Modified RECIST (mRECIST) assessment for hepatocellular carcinoma","volume":"30","author":"Lencioni","year":"2010","journal-title":"Semin Liver Dis"},{"key":"R8-20260814","doi-asserted-by":"crossref","first-page":"e232408","DOI":"10.1148\/radiol.232408","article-title":"CT\/MRI LI-RADS 2024 update: treatment response assessment","volume":"313","author":"Aslam","year":"2024","journal-title":"Radiology"},{"key":"R9-20260814","doi-asserted-by":"crossref","first-page":"233","DOI":"10.2147\/JHC.S358082","article-title":"Systemic therapy for hepatocellular carcinoma: current updates and outlook","volume":"9","author":"Fan","year":"2022","journal-title":"J Hepatocell Carcinoma"},{"key":"R11-20260814","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1186\/s13244-019-0801-z","article-title":"Assessment of hepatocellular carcinoma treatment response with LI-RADS: a pictorial review","volume":"10","author":"Voizard","year":"2019","journal-title":"Insights Imaging"},{"key":"R12-20260814","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s40364-021-00350-4","article-title":"Recent advances in systemic therapy for hepatocellular carcinoma","volume":"10","author":"Zhang","year":"2022","journal-title":"Biomark Res"},{"key":"R13-20260814","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3350\/cmh.2023.0125","article-title":"Recent advances in the management of hepatocellular carcinoma","volume":"30","author":"Sankar","year":"2024","journal-title":"Clin Mol Hepatol"},{"key":"R14-20260814","first-page":"1073274817744621","article-title":"Liver resection and surgical strategies for management of primary liver cancer","volume":"25","author":"Orcutt","year":"2018","journal-title":"Cancer Control J Moffitt Cancer Cent"},{"key":"R15-20260814","first-page":"31","article-title":"International criteria for measurement of tumour response","volume":"2","author":"Ollivier","year":"2001","journal-title":"Cancer Imaging"},{"key":"R16-20260814","doi-asserted-by":"crossref","first-page":"121","DOI":"10.4103\/0971-3026.155835","article-title":"Imaging for assessment of treatment response in hepatocellular carcinoma: current update","volume":"25","author":"Hayano","year":"2015","journal-title":"Indian J Radiol Imaging"},{"key":"R17-20260814","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1148\/radiol.11110282","article-title":"Which response criteria best help predict survival of patients with hepatocellular carcinoma following chemoembolization? A validation study of old and new models","volume":"262","author":"Shim","year":"2012","journal-title":"Radiology"},{"key":"R18-20260814","doi-asserted-by":"crossref","first-page":"20130811","DOI":"10.1259\/bjr.20130811","article-title":"Perfusion CT imaging of colorectal cancer","volume":"87","author":"Goh","year":"2014","journal-title":"Br J Radiol"},{"key":"R19-20260814","doi-asserted-by":"crossref","first-page":"W11","DOI":"10.2214\/AJR.13.12412","article-title":"CT perfusion as an imaging biomarker in monitoring response to neoadjuvant bevacizumab and radiation in soft-tissue sarcomas: comparison with tumor morphology, circulating and tumor biomarkers, and gene expression","volume":"204","author":"Kambadakone","year":"2015","journal-title":"AJR Am J Roentgenol"},{"key":"R20-20260814","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1102\/1470-7330.2013.0040","article-title":"Quantitative characterization of hepatocellular carcinoma and metastatic liver tumor by CT perfusion","volume":"13","author":"Hayano","year":"2013","journal-title":"Cancer Imaging"},{"key":"R21-20260814","doi-asserted-by":"crossref","first-page":"e190024","DOI":"10.1148\/rycan.2020190024","article-title":"MRI assessment of hepatocellular carcinoma after local-regional therapy: a comprehensive review","volume":"2","author":"Mendiratta-Lala","year":"2020","journal-title":"Radiol Imaging Cancer"},{"key":"R22-20260814","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.jhep.2019.09.026","article-title":"mRECIST for HCC: performance and novel refinements","volume":"72","author":"Llovet","year":"2020","journal-title":"J Hepatol"},{"key":"R23-20260814","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada","volume":"92","author":"Therasse","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"R24-20260814","doi-asserted-by":"crossref","first-page":"W88","DOI":"10.2214\/AJR.15.15490","article-title":"Current guidelines for the diagnosis and management of hepatocellular carcinoma: a comparative review","volume":"207","author":"Arslanoglu","year":"2016","journal-title":"AJR Am J Roentgenol"},{"key":"R25-20260814","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.2217\/fon-2018-0747","article-title":"Assessment of the response of hepatocellular carcinoma to interventional radiology treatments","volume":"15","author":"Patella","year":"2019","journal-title":"Future Oncol Lond Engl"},{"key":"R26-20260814","doi-asserted-by":"crossref","first-page":"e052294","DOI":"10.1136\/bmjopen-2021-052294","article-title":"RECIST 1.1 versus mRECIST for assessment of tumour response to molecular targeted therapies and disease outcomes in patients with hepatocellular carcinoma: a systematic review and meta-analysis","volume":"12","author":"Yu","year":"2022","journal-title":"BMJ Open"},{"key":"R27-20260814","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1148\/radiol.2015142951","article-title":"Comparison of existing response criteria in patients with hepatocellular carcinoma treated with transarterial chemoembolization using a 3D quantitative approach","volume":"278","author":"Tacher","year":"2016","journal-title":"Radiology"},{"key":"R28-20260814","doi-asserted-by":"crossref","first-page":"S28","DOI":"10.1016\/j.jvir.2015.12.084","article-title":"Which response criteria can predict early tumor response in CT image in hepatocellular carcinoma patients treated with TACE: RECIST, mRECIST, EASL or qEASL?","volume":"27","author":"Zhao","year":"2016","journal-title":"J Vasc Interv Radiol"},{"key":"R29-20260814","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1148\/radiol.14132361","article-title":"CT and MR imaging diagnosis and staging of hepatocellular carcinoma: part I. Development, growth, and spread: key pathologic and imaging aspects","volume":"272","author":"Choi","year":"2014","journal-title":"Radiology"},{"key":"R30-20260814","doi-asserted-by":"crossref","first-page":"e000146","DOI":"10.1136\/jitc-2019-000146","article-title":"Comparison of iRECIST versus RECIST V.1.1 in patients treated with an anti-PD-1 or PD-L1 antibody: pooled FDA analysis","volume":"8","author":"Mulkey","year":"2020","journal-title":"J Immunother Cancer"},{"key":"R31-20260814","doi-asserted-by":"crossref","first-page":"e143","DOI":"10.1016\/S1470-2045(17)30074-8","article-title":"iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics","volume":"18","author":"Seymour","year":"2017","journal-title":"Lancet Oncol"},{"key":"R32-20260814","doi-asserted-by":"crossref","first-page":"764189","DOI":"10.3389\/fonc.2021.764189","article-title":"Response evaluation and survival prediction following PD-1 inhibitor in patients with advanced hepatocellular carcinoma: comparison of the RECIST 1.1, iRECIST, and mRECIST criteria","volume":"11","author":"Zhou","year":"2021","journal-title":"Front Oncol"},{"key":"R33-20260814","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/hepr.12542","article-title":"Response evaluation criteria in cancer of the liver (RECICL) (2015 revised version)","volume":"46","author":"Kudo","year":"2016","journal-title":"Hepatol Res"},{"key":"R34-20260814","doi-asserted-by":"crossref","first-page":"738","DOI":"10.4254\/wjh.v12.i10.738","article-title":"Hepatocellular carcinoma liver imaging reporting and data systems treatment response assessment: lessons learned and future directions","volume":"12","author":"Aslam","year":"2020","journal-title":"World J Hepatol"},{"key":"R35-20260814","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1007\/s00261-011-9683-3","article-title":"Assessment of the treatment response of HCC","volume":"36","author":"Kim","year":"2011","journal-title":"Abdom Imaging"},{"key":"R36-20260814","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1007\/s00261-011-9750-9","article-title":"Peri-intraprocedural imaging: US, CT, and MRI","volume":"36","author":"Crocetti","year":"2011","journal-title":"Abdom Imaging"},{"key":"R37-20260814","doi-asserted-by":"crossref","first-page":"e021269","DOI":"10.1136\/bmjopen-2017-021269","article-title":"Comparative efficacy of treatment strategies for hepatocellular carcinoma: systematic review and network meta-analysis","volume":"8","author":"Tian","year":"2018","journal-title":"BMJ Open"},{"key":"R38-20260814","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1007\/s00261-008-9454-y","article-title":"Radiologic findings following Y90 radioembolization for primary liver malignancies","volume":"34","author":"Ibrahim","year":"2009","journal-title":"Abdom Imaging"},{"key":"R39-20260814","first-page":"245","article-title":"Extending the frontiers beyond thermal ablation by radiofrequency ablation: SBRT, brachytherapy, SIRT (radioembolization)","volume":"30","author":"Hass","year":"2014","journal-title":"Viszeralmedizin"},{"key":"R40-20260814","doi-asserted-by":"crossref","first-page":"3698","DOI":"10.1007\/s00261-020-02532-4","article-title":"Natural history of hepatocellular carcinoma after stereotactic body radiation therapy","volume":"45","author":"Mendiratta-Lala","year":"2020","journal-title":"Abdom Radiol N Y"},{"key":"R41-20260814","doi-asserted-by":"crossref","first-page":"80","DOI":"10.2214\/AJR.13.10706","article-title":"Imaging assessment of hepatocellular carcinoma response to locoregional and systemic therapy","volume":"201","author":"Yaghmai","year":"2013","journal-title":"AJR Am J Roentgenol"},{"key":"R42-20260814","first-page":"589","article-title":"Oncologic applications of dual-energy CT in the abdomen","volume":"34","author":"Agrawal","year":"2014","journal-title":"Radiogr Rev Publ Radiol Soc N Am Inc"},{"key":"R43-20260814","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1007\/s11547-021-01366-4","article-title":"Advanced CT techniques for assessing hepatocellular carcinoma","volume":"126","author":"Nakamura","year":"2021","journal-title":"Radiol Med (Torino)"},{"key":"R44-20260814","doi-asserted-by":"crossref","first-page":"879","DOI":"10.3390\/jcm12030879","article-title":"The role of dual-energy CT for the assessment of liver metastasis response to treatment: above the RECIST 1.1 criteria","volume":"12","author":"Reginelli","year":"2023","journal-title":"J Clin Med"},{"issue":"5 Suppl","key":"R45-20260814","doi-asserted-by":"crossref","first-page":"S98","DOI":"10.2214\/AJR.12.9207","article-title":"Dual-energy CT: oncologic applications","volume":"199","author":"De Cecco","year":"2012","journal-title":"AJR Am J Roentgenol"},{"key":"R46-20260814","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1186\/s43055-021-00660-5","article-title":"CT perfusion for response evaluation after interventional ablation of hepatocellular carcinoma: a prospective study","volume":"52","author":"Osman","year":"2021","journal-title":"Egypt J Radiol Nucl Med"},{"key":"R47-20260814","doi-asserted-by":"crossref","first-page":"3125","DOI":"10.3748\/wjg.v20.i12.3125","article-title":"DCE-MRI in hepatocellular carcinoma-clinical and therapeutic image biomarker","volume":"20","author":"Chen","year":"2014","journal-title":"World J Gastroenterol"},{"key":"R48-20260814","doi-asserted-by":"crossref","first-page":"3579","DOI":"10.1007\/s00261-021-03059-y","article-title":"Contrast-enhanced ultrasound (CEUS) in HCC diagnosis and assessment of tumor response to locoregional therapies","volume":"46","author":"Eisenbrey","year":"2021","journal-title":"Abdom Radiol N Y"},{"key":"R49-20260814","first-page":"360","article-title":"Positron emission tomography and molecular imaging","volume":"94","author":"Knuuti","year":"2008","journal-title":"Heart Br Card Soc"},{"key":"R50-20260814","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.cpet.2016.05.004","article-title":"PET\/MR imaging in cancers of the gastrointestinal tract","volume":"11","author":"Paspulati","year":"2016","journal-title":"PET Clin"},{"key":"R51-20260814","doi-asserted-by":"crossref","first-page":"3727","DOI":"10.1002\/cncr.33772","article-title":"Positron emission tomography\/computed tomography in the management of Hodgkin and B-cell non-Hodgkin lymphoma: an update","volume":"127","author":"Juweid","year":"2021","journal-title":"Cancer"},{"key":"R52-20260814","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.3390\/cancers15071975","article-title":"Update on PET radiopharmaceuticals for imaging hepatocellular carcinoma","volume":"15","author":"Nyakale","year":"2023","journal-title":"Cancers"},{"key":"R53-20260814","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1148\/radiol.2015151169","article-title":"Radiomics: images are more than pictures, they are data","volume":"278","author":"Gillies","year":"2016","journal-title":"Radiology"},{"key":"R54-20260814","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1102\/1470-7330.2013.9045","article-title":"CT texture analysis using the filtration-histogram method: what do the measurements mean?","volume":"13","author":"Miles","year":"2013","journal-title":"Cancer Imaging"},{"key":"R55-20260814","first-page":"1483","article-title":"CT texture analysis: definitions, applications, biologic correlates, and challenges","volume":"37","author":"Lubner","year":"2017","journal-title":"Radiogr Rev Publ Radiol Soc N Am Inc"},{"key":"R56-20260814","first-page":"156","article-title":"Assessment of Y-90 radioembolization treatment response for hepatocellular carcinoma cases using MRI radiomics","volume":"33","author":"Mahmoud","year":"2024","journal-title":"Mol Imaging Radionucl Ther"},{"key":"R57-20260814","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.acra.2023.09.008","article-title":"Radiomics-based machine learning to predict the recurrence of hepatocellular carcinoma: a systematic review and meta-analysis","volume":"31","author":"Jin","year":"2024","journal-title":"Acad Radiol"},{"key":"R58-20260814","doi-asserted-by":"crossref","first-page":"3674","DOI":"10.1007\/s00261-021-03085-w","article-title":"Radiomics of hepatocellular carcinoma: promising roles in patient selection, prediction, and assessment of treatment response","volume":"46","author":"Borhani","year":"2021","journal-title":"Abdom Radiol N Y"},{"key":"R59-20260814","doi-asserted-by":"crossref","first-page":"6123","DOI":"10.3390\/cancers14246123","article-title":"The role of radiomics and AI technologies in the segmentation, detection, and management of hepatocellular carcinoma","volume":"14","author":"Fahmy","year":"2022","journal-title":"Cancers"},{"key":"R60-20260814","doi-asserted-by":"crossref","first-page":"3660","DOI":"10.1007\/s00261-021-03056-1","article-title":"Artificial intelligence in assessment of hepatocellular carcinoma treatment response","volume":"46","author":"Spieler","year":"2021","journal-title":"Abdom Radiol N Y"},{"key":"R61-20260814","doi-asserted-by":"crossref","first-page":"15330338221141793","DOI":"10.1177\/15330338221141793","article-title":"Artificial intellgence in the era of precision oncological imaging","volume":"21","author":"Cellina","year":"2022","journal-title":"Technol Cancer Res Treat"},{"key":"R62-20260814","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1136\/gutjnl-2018-316204","article-title":"Deep learning Radiomics of shear wave elastography significantly improved diagnostic performance for assessing liver fibrosis in chronic hepatitis B: a prospective multicentre study","volume":"68","author":"Wang","year":"2019","journal-title":"Gut"},{"key":"R63-20260814","first-page":"464","article-title":"EFSUMB guidelines on interventional ultrasound (INVUS), part I. General aspects (short version)","volume":"36","author":"Lorentzen","year":"2015","journal-title":"Ultraschall Med Stuttg Ger 1980"},{"key":"R64-20260814","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.ejrad.2018.05.030","article-title":"Ablation treatment of primary and secondary liver tumors under contrast-enhanced ultrasound guidance in field practice of interventional ultrasound centers. A multicenter study","volume":"105","author":"Francica","year":"2018","journal-title":"Eur J Radiol"},{"key":"R65-20260814","doi-asserted-by":"crossref","first-page":"411","DOI":"10.7863\/ultra.34.3.411","article-title":"Real-time contrast-enhanced sonographically guided biopsy or radiofrequency ablation of focal liver lesions using perflurobutane microbubbles (sonazoid): value of Kupffer-phase imaging","volume":"34","author":"Park","year":"2015","journal-title":"J Ultrasound Med"},{"key":"R66-20260814","first-page":"4","article-title":"Contrast-enhanced ultrasonography for the evaluation of malignant focal liver lesions","volume":"41","author":"Chammas","year":"2022","journal-title":"Ultrason Seoul Korea"},{"key":"R67-20260814","doi-asserted-by":"crossref","first-page":"100327","DOI":"10.1016\/j.medntd.2024.100327","article-title":"Hepatocellular carcinoma imaging: Exploring traditional techniques and emerging innovations for early intervention","volume":"24","author":"Vengateswaran","year":"2024","journal-title":"Med Nov Technol Devices"},{"key":"R68-20260814","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1002\/jum.14534","article-title":"Contrast-enhanced ultrasonography versus contrast-enhanced computed tomography for assessment of residual tumor from hepatocellular carcinoma treated with transarterial chemoembolization: a meta-analysis","volume":"37","author":"Zhong","year":"2018","journal-title":"J Ultrasound Med"},{"key":"R69-20260814","doi-asserted-by":"crossref","first-page":"437","DOI":"10.2147\/JHC.S353914","article-title":"Application of the CT\/MRI LI-RADS treatment response algorithm to contrast-enhanced ultrasound: a feasibility study","volume":"9","author":"Ruan","year":"2022","journal-title":"J Hepatocell Carcinoma"}],"container-title":["Journal of Computer Assisted Tomography"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/RCT.0000000000001789","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T19:02:02Z","timestamp":1786734122000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/RCT.0000000000001789"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,7]]},"references-count":67,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/rct.0000000000001789","relation":{},"ISSN":["1532-3145"],"issn-type":[{"value":"1532-3145","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,7]]},"assertion":[{"value":"2025-04-24","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-07-01","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}